ERBB2 and neoplasm: The TREAT CTC trial, in which 1317 patients with HER2-negative primary tumour and high levels of CTCs even after neoadjuvant chemotherapy received trastuzumab therapy for 18 weeks, concluded that CTC-based screening is possible in early breast cancer.